Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

BMS to Study Opdivo in Combination with Novartis' Lung Cancer Drugs

October 6, 2014 2:42 pm | News | Comments

 Bristol-Myers Squibb Company announced the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of combining Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) with three molecularly targeted oncology therapies (Zykadia (ceritinib), INC280 and EGF816) from Novartis. Read more...

TOPICS:

Actavis Buying Durata Therapeutics for $616.4

October 6, 2014 10:39 am | News | Comments

Specialty pharmaceutical company Actavis is buying Durata Therapeutics Inc. for about $616.4 million to help bolster its infectious disease portfolio. Read more...                                    

TOPICS:

Teva Announces Results of Review of Core Specialty Therapeutic Areas

October 6, 2014 10:32 am | News | Comments

Teva Pharmaceutical announced results of its strategic review of core therapeutic areas for the company. The review included an extensive evaluation of Teva’s current and future capabilities to address unmet patient needs, the competitive landscape, barriers to entry and profitability with the purpose of creating a winning strategy to achieve global leadership in each of the company's core therapeutic areas. Read more...

TOPICS:
Advertisement

Alcobra Gets Positive Results for Adult ADHD Drug

October 6, 2014 10:22 am | News | Comments

Alcobra Ltd., an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced topline results from a Phase 3 study of Metadoxine Extended Release (MDX) in adults with ADHD. Read more...

TOPICS:

‘Programmable’ Antibiotic Harnesses Enzyme to Attack Drug-Resistant Microbes

October 6, 2014 10:12 am | News | Comments

The multitude of microbes scientists have found populating the human body have good, bad and mostly mysterious implications for our health. But when something goes wrong, we defend ourselves with the undiscriminating brute force of traditional antibiotics, which wipe out everything at once, regardless of the consequences. Read more...

TOPICS:

Journalist with Ebola Arrives at Nebraska Hospital

October 6, 2014 9:57 am | by Josh Funk | News | Comments

An American video journalist who contracted Ebola while working in Liberia has arrived at a Nebraska hospital, where he will be treated for the deadly disease. Ashoka Mukpo, 33, arrived by ambulance Monday at the Nebraska Medical Center, where he will be kept in a specialized biocontainment unit built specifically to handle this type of illness. Read more...

TOPICS:

Sanofi Signs 15-Year Supply Agreement for Wearable Injectors with Unilife

October 6, 2014 9:47 am | News | Comments

Unilife Corporation, a developer and supplier of injectable drug delivery systems, announced the signing of a worldwide Master Services and Commercial Supply Agreement with Sanofi to be the sole provider of cartridge based wearable injectors for all of Sanofi's applicable large dose volume drugs, excluding insulins, for a minimum 15 years. Read more...

TOPICS:

CEL-SCI Enrolls 16 New Patients in Phase 3 Cancer Trial

October 3, 2014 3:33 pm | News | Comments

CEL-SCI Corp. announced that during the month of September the company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase 3 trial. Read more...             

TOPICS:
Advertisement

New Technology Isolates Tumor Cells from Blood to Optimize Cancer Therapy

October 3, 2014 3:29 pm | News | Comments

A team of bioengineers, molecular biologists, and clinicians used a novel rare cell-sorter to isolate breast cancer cells from the blood of patients, with the aim of identifying the most effective drugs to treat each individual tumor. Read more...

TOPICS:

Fasting Blood Biomarker a-HB Predicts Diabetes Risk

October 3, 2014 3:11 pm | News | Comments

Could a single serum biomarker predict risk for diabetes as accurately as a more complex, hours-long diagnostic procedure? According to researchers at Health Diagnostic Laboratory Inc. and the University of Utah, the answer is "yes." Read more...

TOPICS:

Neurocrine Initiates Clinical Trial for Tourette Syndrome Therapy

October 3, 2014 2:58 pm | News | Comments

Neurocrine Biosciences, Inc. announced that it has initiated a clinical trial of NBI-98854, a proprietary small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in both children and adolescents with Tourette syndrome. Read more...      

TOPICS:

Halozyme Gets Orphan Drug Designation for Pancreatic Cancer Drug

October 3, 2014 2:49 pm | News | Comments

Halozyme Therapeutics, Inc. announced that the FDA has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer. Read more...                             

TOPICS:

Record Number of Clinical Trials for Multiple Myeloma this Year

October 3, 2014 2:11 pm | News | Comments

The Multiple Myeloma Research Consortium (MMRC) announced that it has opened six new clinical trials in 2014, and is on track to open more multiple myeloma clinical trials during 2014 than any other year since the Consortium was founded in 2004. Read more...

TOPICS:

Potential Therapy Spotted for Sudan Strain of Ebola

October 3, 2014 11:04 am | by Stephanie Guzowski, Editor | Articles | Comments

As the deadly Ebola outbreak in West Africa continues to grip headlines around the world, researchers move steadily forward with drug development. But as essential as it is to contain the current Ebola outbreak, researchers are looking at the bigger picture— and highlighting the need for therapy development to extend beyond the wake of the current epidemic. Read more...

TOPICS:

Ancient Protein-Making Enzyme Moonlights as DNA Protector

October 3, 2014 10:54 am | News | Comments

Scientists at TSRI have found that an enzyme best known for its fundamental role in building proteins has a second major function: to protect DNA during times of cellular stress. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading